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4-Pyridoxolactonase from Mesorhizobium loti MAFF303099 has been over-
expressed in Escherichia coli. The recombinant enzyme was purified and was
crystallized by the sitting-drop vapour-diffusion method using PEG 4000 and
ammonium sulfate as precipitants. Crystals of the free enzyme (form I) and of
the 5-pyridoxolactone-bound enzyme (form II) grew under these conditions.
Crystals of form I diffracted to 2.0 A˚ resolution and belonged to the monoclinic
space group C2, with unit-cell parameters a = 77.93, b = 38.88, c = 81.60 A˚,
 = 117.33. Crystals of form II diffracted to 1.9 A˚ resolution and belonged to
the monoclinic space group C2, with unit-cell parameters a = 86.24, b = 39.35,
c = 82.68 A˚, = 118.02. The calculated VM values suggested that the asymmetric
unit contains one molecule in both crystal forms.
1. Introduction
4-Pyridoxolactonase (EC 3.1.1.27) is involved in degradation pathway
I of pyridoxine, a free (phosphate-unbound) form of vitamin B6. The
enzyme catalyzes the hydrolysis of 4-pyridoxolactone to 4-pyridoxic
acid (Fig. 1a). The enzyme has been purified from Pseudomonas
MA-1 (Jong & Snell, 1986) and Mesorhizobium loti (Funami et al.,
2005) cells. The enzyme from M. loti, a nitrogen-fixing symbiotic
bacterium, has been cloned and sequenced and a recombinant
4-pyridoxolactonase has been characterized. Sequence comparisons
suggest that M. loti 4-pyridoxolactonase is a member of the metallo-
hydrolase-family proteins with, for example, 33% identity to the
AttM/AiiB protein from Agrobacterium tumefaciens strain A6 and
30% identity to the acylhomoserine lactonase from Bacillus thur-
ingiensis (Altschul et al., 1997). 4-Pyridoxolactonase contains three
characteristic histidine residues which are probably involved in the
binding of one Zn atom as in other metallohydrolase-family proteins
(Funami et al., 2005).
Although 4-pyridoxolactonase shows activity towards 4-pyridoxo-
lactone in the degradation pathway, it can also hydrolyzeN-hexanoyl-
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Figure 1
Reactions catalyzed by 4-pyridoxolactonase. (a) Hydrolysis of 4-pyridoxolactone
to 4-pyridoxic acid. (b) Hydrolysis of N-hexanoyl-d,l-homoserine lactone to
N-hexanoyl-d,l-homoserine.
d,l-homoserine lactone (Fig. 1b): its activity towards the latter
compound is 41% of that towards the former (Funami et al., 2005).
N-Hexanoyl-d,l-homoserine lactone interferes with the quorum-
sensing systems of Gram-negative bacteria (Dong et al., 2001). These
results suggested the possibility that 4-pyridoxolactonase could play
a role in the quorum-sensing systems of M. loti (a Gram-negative
bacterium) cells.
Tertiary structures of N-acylhomoserine lactone lactonase have
been reported (Liu et al., 2005; Kim et al., 2005) and the mode of
interaction between the product and two Zn atoms in the active site
(Liu et al., 2008) has also been reported. In contrast, 4-pyridoxo-
lactonase contains only one Zn atom in the active site. Thus, its
reaction mechanism should be considerably different from that of
N-acylhomoserine lactone lactonase and needs to be elucidated
based on its tertiary structure and active-site environment. Here, we
describe the crystallization and preliminary X-ray diffraction studies
of 4-pyridoxolactonase from M. loti.
2. Material and methods
2.1. Overexpression and purification of 4-pyridoxolactonase
The overexpression and purification of 4-pyridoxolactonase have
previously been reported (Funami et al., 2005); one additional puri-
fication step was used for crystallization. Briefly, the enzyme was
overexpressed in Escherichia coli BL21 (DE3) cells harbouring
plasmid pET21a6805 and purified sequentially by Butyl-Toyopearl
650M and QA52 column chromatography. The enzyme fraction
eluted from the QA52 column was concentrated by ammonium
sulfate precipitation. The precipitate was dissolved in a minute
amount of 10 mM HEPES–KOH pH 7.5 containing 0.1%(v/v)
2-mercaptoethanol and 10%(w/v) glycerol (buffer A) and the enzyme
solution was applied onto a hydroxylapatite column (Wako Pure
Chemicals, Osaka, Japan). The enzyme was eluted with buffer A
containing 20 mM potassium phosphate pH 7.5 and the purified
enzyme was dialyzed against 10 mM HEPES pH 7.0 containing
0.1%(v/v) 2-mercaptoethanol. The enzyme was concentrated using an
Ultrafree C31GC (Millipore, Billerica, Massachusetts, USA).
2.2. Crystallization and X-ray analysis
The initial crystallization conditions were screened using Crystal
Screen I, PEG/Ion Screen (Hampton Research, California, USA) and
Wizard Screens I and II (Emerald BioSystems Inc., Washington,
USA). The enzyme was crystallized at 277 K by the sitting-drop
vapour-diffusion method using CrystalClear Strips from Hampton
Research (Laguna Niguel, California, USA). Crystals appeared
during equilibration of a droplet consisting of a mixture of the same
volumes (2 ml) of protein solution and reservoir solution against a
reservoir containing 100 ml reservoir solution using PEG/Ion Screen
condition Nos. 16 and 19. After improvement of the conditions, the
reservoir solution was changed to 200 mM ammonium acetate,
100 mM sodium acetate and 30%(w/v) PEG 4000 (final pH 7.5). Thus,
the most suitable conditions for crystallization to produce crystals of
the free enzyme (form I) were determined to be a mixture of 2 ml
enzyme solution (6.4 mg ml1) and 2 ml reservoir solution. Crystals of
the enzyme grew from the droplets in two weeks when the enzyme
mixture was equilibrated against 100 ml reservoir solution at 277 K.
The enzyme was also crystallized in the presence of 5-pyridoxo-
lactone, a competitive inhibitor (Jong & Snell, 1986), to produce form
II crystals. Enzyme solution (2 ml, 6.4 mg ml1) containing 0.75 mM
5-pyridoxolactone was mixed with 2 ml reservoir solution [200 mM
ammonium acetate, 100 mM sodium acetate, 30%(w/v) PEG 4000
(final pH 7.0)] and the mixture was equilibrated against a reservoir
containing 100 ml reservoir solution at 277 K. Crystals of the enzyme–
inhibitor complex grew in two weeks.
A form I crystal picked up from a droplet was transferred into
cryoprotectant solution [25%(v/v) glycerol, 20 mM ammonium
acetate, 100 mM sodium acetate and 30%(w/v) PEG 4000 (final pH
7.5)]. The crystal was placed into a cold nitrogen-gas stream at 100 K.
The form II crystal was placed into a cold nitrogen-gas stream
without cryoprotectant treatment. X-ray diffraction images were
collected from the crystals at 100 K in the nitrogen-gas stream with a
Rigaku Jupiter 201 CCD detector using synchrotron radiation of
wavelength 1.00 A˚ at station BL38B1 of SPring-8 (Hyogo, Japan).
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Figure 2
SDS–PAGE analysis of purified 4-pyridoxolactonase. Lane 1, molecular markers
(kDa). Lane 2, purified 4-pyridoxolactonase for crystallization.
Figure 3
Crystals of 4-pyridoxolactonase. (a) Crystal of form I. (b) Crystal of form II, in
which the enzyme binds 5-pyridoxolactone. The scale bars are 0.1 mm in length.
The crystal-to-detector distances for the form I and form II crystals
were set to 183.5 and 184.5 mm, respectively. Oscillation images of
0.5 and 1.0 were recorded for form I and form II crystals, respec-
tively, with an exposure time of 6 s.
2.3. Enzyme assay
4-Pyridoxolactonase activity was determined by measuring the
initial decrease in the A356 of 4-pyridoxolactone (" = 8.0 mM
1 cm1)
at 298 K in a reaction mixture (1.0 ml) consisting of 100 mM potas-
sium phosphate buffer pH 7.5, 0.1 mM 4-pyridoxolactone and the
enzyme. One unit of enzyme was defined as the amount of enzyme
that catalyzed the hydrolysis of 1 mmol of the substrate per minute.
3. Results and discussion
4-Pyridoxolactonase was successfully overexpressed in E. coli and
purified, maintaining significant enzyme activity. The results of SDS–
PAGE analysis of the purified enzyme are shown in Fig. 2.
Crystals suitable for X-ray data collection were obtained.
Diffraction data were obtained from form I (Fig. 3a) and form II
(Fig. 3b) crystals in the resolution ranges 50–2.00 and 50–1.90 A˚,
respectively, and were processed using the HKL-2000 program
package (DENZO and SCALEPACK; Otwinowski & Minor, 1997).
Crystal parameters and diffraction data statistics are summarized in
Table 1. The space group of the both crystals was determined to be C2
(monoclinic), with unit-cell parameters a = 77.93, b = 38.88,
c = 81.60 A˚,  = 117.33 for form I and a = 86.24, b = 39.35,
c = 82.68 A˚,  = 118.02 for form II. From the total of 75 700
reflections measured for the form I crystal, 14 565 independent
reflections were obtained with an Rmerge value of 8.2%. The data set
was 98.0% complete at the resolution limit of 2.0 A˚ (Fig. 4a). Simi-
larly, from the total of 103 324 reflections measured for the form II
crystal, 19 769 independent reflections were obtained with an Rmerge
value of 5.0%. The data set was 99.5% complete at the resolution
limit of 1.90 A˚ (Fig. 4b). The VM value (Matthews, 1968), the crystal
volume per unit protein molecular weight, for the form I crystal was
calculated to be 1.77 A˚3 Da1 assuming the presence of one molecule
of the enzyme in the asymmetric unit, with a solvent content of
30.6%. The VM value for the form II crystal was 2.00 A˚
3 Da1
assuming the presence of one molecule of the enzyme in the asym-
metric unit, with a solvent content of 38.5%. The VM values and
solvent contents lie within the ranges usually found for protein
crystals, although they are lower than the mean values.
We are currently preparing a selenomethionine derivative of the
enzyme for further analysis.
We thank Dr K. Hasegawa of Japan Synchrotron Radiation
Research Institute (JASRI) for his kind help in data collection. X-ray
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Table 1
Data-collection statistics for crystals of 4-pyridoxolactonase.
Values in parentheses are for the highest resolution shell.
Form I Form II
X-ray source SPring-8 (BL26B1) SPring-8 (BL38B1)
Wavelength (A˚) 1.0000 1.0000
Detector Jupiter 201 (1  1 bin mode) Jupiter 201 (1  1 bin mode)
Crystal system Monoclinic Monoclinic
Space group C2 C2
Unit-cell parameters
(A˚, )
a = 77.93, b = 38.88,
c = 81.60,  = 117.33
a = 86.24, b = 39.35,
c = 82.68,  = 118.02
Processing software HKL-2000 HKL-2000
Resolution limit (A˚) 50–2.00 (2.07–2.00) 50–1.90 (1.96–1.90)
Measured reflections 75780 103324
Redundancy 5.2 (4.3) 5.2 (4.6)
Unique reflections 14565 (1389) 19769 (1867)
Completeness (%) 98.0 (93.5) 99.5 (95.7)
hI/(I)i 8.5 23.6
Rmerge (%) 8.2 (34.9) 5.0 (10.0)
Figure 4
Diffraction images ofM. loti 4-pyridoxolactonase. (a) Form I crystal with a resolution scale of 1.9 A˚ indicated by the ring. (b) Form II crystal with a resolution scale of 1.9 A˚
indicated by the ring.
data collection at BL38B1 of SPring-8 was carried out with the
approval of the organizing committee of SPring-8.
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